colorectal cancer news from FierceBiotech
NewsAstraZeneca's Recentin fails lung cancer trial
AstraZeneca says it will push ahead with late-stage studies of Recentin for colorectal cancer after shelving plans for a Phase III in non-small cell lung cancer due to toxicity concerns. The Read more...
Matuzumab in doubt after trial failure
There's trouble at Merck Serono's program for Matuzumab, which is in development for colorectal cancer. Merck KGaA says it is "reconsidering" further development of the therapy after the Read more...
Press Release: Results Show XELOX Provides Equivalent Overall Patient Survival Compared To FOLFOXPress Release: Results Show XELOX Provides Equivalent Overall Patient Survival Compared To FOLFOX Read more...Press Release: Xeloda Combination Meets Primary Endpoint in Phase III StudyPress Release: Xeloda Combination Meets Primary Endpoint in Phase III Study Read more...Amgen launches price war on Vectibix OKAfter winning the FDA's approval for its new cancer drug Vectibix, Amgen swiftly pegged the price of the new drug at a 20 percent discount on Erbitux, which works in much the same way. Analysts immediately seized on the move as an indication that the biopharma industry is becoming increasingly sensitive to criticisms that new cancer therapies are priced at huge premiums for drug developers. But even at the discount, analysts note, Vectibix will still cost more than $100,000 a year. Most … Read more...ALSO NOTED: Takeda may scrap licensing deal; Humira approved for new use;and much more...> Disappointed by poor efficacy data from two Phase III trials of Tavocept, Japan's Takeda announced that it has told BioNumerik Pharmaceuticals that it may scrap their licensing deal on the drug. Report > The FDA has approved Abbott's Humira for an inflammatory disease of the spine and spinal joints. Report > Shares … Read more...ALSO NOTED: Companies compete for microdosing tests; Bayer to expand facility; and much more...> Two small U.S. companies are competing to make the first tests that will register results for newly-allowed microdosing trials. Under new FDA rules, drug developers can test tiny amounts of experimental therapies in humans to get some insight into efficacy before launching expensive studies. The potential specialized drug testing market for microdosing is estimated at $500 million. Report > … Read more...C&L: Tedford resigns early from Patheon
Contract drug manufacturer Patheon has announced that Robert Tedford has turned in his resignation 10 months ahead of schedule. Patheon chairman Peter Green, president and CEO Nick DiPietro, and CFO and executive vice-president Douglas Ludwig have formed the "office of the chief … Read more...ALSO NOTED: Serono files sBLA for Rebif; Germany's Ingenium raises €9.2M in VC; and much more...> Switzerland's Serono has filed a supplemental BLA for a new formulation of its MS drug Rebif. According to Phase III data, the new formulation is more easily tolerated by patients. Report > Achillion Pharmaceuticals has filed for a $75 million IPO. Report > Germany's Ingenium has raised €9.2 million … Read more...Spectrum acquires Targent cancer assetsSpectrum Pharmaceuticals is buying Targent's cancer drug assets in a deal that could potentially be worth more than $6.5 million. Spectrum will pay Target 600,000 shares for the cancer assets, which primarily involves levofolinic acid, and up to 650,000 shares more for certain regulatory and sales milestones. An NDA has been filed for levofolinic acid as a therapy for bone cancer. The drug has been assigned orphan status as a combination therapy with existing chemotherapies for bone … Read more... | Press ReleasesPRESS RELEASE: Merck Serono to Reconsider Development of Matuzumab in Metastatic Colorectal Cancer Patients Merck Serono to Reconsider Development of Matuzumab in Metastatic Colorectal Cancer Patients DARMSTADT, Germany, August 29, 2007 - Merck Serono, a division of Merck KGaA, announced today that a Read more... |
Get more colorectal cancer coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets